This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Remedy Informatics First And Only Vendor Authorized To Submit Full Suite Of AGNIS-Supported CIBMTR Forms, Launches "Live In Five" Software Deployment Program

SALT LAKE CITY, Feb. 13, 2013 /PRNewswire/ -- Remedy Informatics today announced that it is the first vendor authorized by the Center for International Blood & Marrow Transplant Research (CIBMTR) to submit all CIBMTR forms currently supported by CIBMTR's AGNIS system. This achievement represents a significant milestone in Remedy's efforts to help its clients improve clinical outcomes for BMT patients by giving BMT centers the tools necessary to easily access and analyze clinical data.


Remedy officially launched its "Live In Five" program, committing to deploy a fully functional instance of ComprehensiveBMT throughout a BMT center in only five business days.

"The purpose of Remedy Informatics' clinical products is to support our clients' efforts to improve patient care by providing software solutions that will accelerate both clinical research and quality improvement initiatives — that is the central focus of ComprehensiveBMT," said Jonathan Dewey, MD, director of clinical products at Remedy Informatics. "Furthermore, our new five-day deployment strategy has already enabled our clients to derive benefits almost immediately. This is unlike traditional institution-wide software installations and deployments that can take months or years, and are often mired in red tape along the way."

Dr. Douglas Rizzo, CIBMTR's Associate Scientific Director for Data Operations and CIBMTR Executive Committee member, corroborated Remedy's claim. "Remedy Informatics has demonstrated the ability to submit data for all CIBMTR forms currently supported by the AGNIS system, and is now authorized by the CIBMTR for this activity in AGNIS," said Rizzo. "Expanded forms submission by Remedy represents one of several examples of increasing utilization of the AGNIS application to automate data exchange with the CIBMTR for the benefit of transplant centers and researchers."

In addition, Remedy Informatics offers a version of its Investigate™ product, specially designed for Cell Therapy labs. InvestigateCT™ is an integrated research management system designed to provide BMT and cell therapy laboratories an end-to-end service line production and research system. InvestigateCT operationalizes cell products biobanking, cell processing laboratory protocols and research study management, all on the same Mosaic™ Platform as ComprehensiveBMT. Which means that both products are automatically able to share data, annotations, results and gain a composite view of each patient, subject or donor.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs